Clinical Trials
57 trialsNCT05264974 2026-05-27
Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization
University of Florida
Phase 1 Suspended
NCT04381806 2026-05-22
Phase I Study in Advanced Malignancies With 5-ALA
Fox Chase Cancer Center
Phase 1 Suspended
NCT05155332 2026-05-20
A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
Phase 1 Suspended
NCT03816319 2026-05-18
TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts
National Cancer Institute (NCI)
Phase 1 Suspended
NCT05372614 2026-05-18
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
National Cancer Institute (NCI)
Phase 1 Suspended
NCT05685602 2026-05-18
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
National Cancer Institute (NCI)
Phase 1 Suspended
NCT04301076 2026-05-13
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
National Cancer Institute (NCI)
Phase 1 Suspended
NCT04539366 2026-05-13
Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial
National Cancer Institute (NCI)
Phase 1 Suspended
NCT04840589 2026-05-13
Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors
National Cancer Institute (NCI)
Phase 1 Suspended
NCT05111561 2026-05-13
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1 Suspended
NCT06102902 2026-05-13
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
National Cancer Institute (NCI)
Phase 1 Suspended
NCT06514261 2026-05-13
Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML
National Cancer Institute (NCI)
Phase 1 Suspended
NCT06802523 2026-05-13
Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Suspended
NCT06860594 2026-05-13
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
National Cancer Institute (NCI)
Phase 1 Suspended
NCT02354547 2026-05-08
A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors
SynerGene Therapeutics, Inc.
Phase 1 Suspended
NCT07388563 2026-05-08
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1 Suspended
NCT07173374 2026-05-01
SCART-P
Shandong Cancer Hospital and Institute
Phase 1 Suspended
NCT05887882 2026-04-24
PNOC028
University of California, San Francisco
Phase 1 Suspended
NCT04266730 2026-04-23
PANDA-VAC
UNC Lineberger Comprehensive Cancer Center
Phase 1 Suspended
NCT05263284 2026-04-23
8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia
City of Hope Medical Center
Phase 1 Suspended
NCT05204147 2026-04-22
Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers
City of Hope Medical Center
Phase 1 Suspended
NCT06741072 2026-04-21
BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants
Ohio State University Comprehensive Cancer Center
Phase 1 Suspended
NCT07529535 2026-04-17
A First-in-Human Study of ALK-N001 for Injection in Patients With Advanced Solid Tumors
Zhejiang Anglikang Pharmaceutical Co., Ltd.
Phase 1 Suspended
NCT04177004 2026-04-15
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
City of Hope Medical Center
Phase 1 Suspended
NCT05866679 2026-04-15
Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging
M.D. Anderson Cancer Center
Phase 1 Suspended
NCT06968195 2026-04-15
Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma
Roswell Park Cancer Institute
Phase 1 Suspended
NCT04485559 2026-04-13
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
University of California, San Francisco
Phase 1 Suspended
NCT06888323 2026-04-13
Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment
National Cancer Institute (NCI)
Phase 1 Suspended
NCT06824701 2026-04-06
TARZAN
University of Utah
Phase 1 Suspended
NCT02333162 2026-03-30
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant
University of Chicago
Phase 1 Suspended
NCT05139056 2026-03-27
Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas
City of Hope Medical Center
Phase 1 Suspended
NCT03494569 2026-03-18
Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome
City of Hope Medical Center
Phase 1 Suspended
NCT06626633 2026-03-12
2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML
University of Maryland, Baltimore
Phase 1 Suspended
NCT06963346 2026-03-09
Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Suspended
NCT05403723 2026-02-19
Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC
University of Maryland, Baltimore
Phase 1 Suspended
NCT03467386 2026-02-17
Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia
City of Hope Medical Center
Phase 1 Suspended
NCT03065062 2026-02-13
Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
Dana-Farber Cancer Institute
Phase 1 Suspended
NCT06492707 2026-02-09
DR-18 for the Treatment of Relapsed or Persistent Acute Myeloid Leukemia or Myelodysplastic Syndrome After Hematopoietic Cell Transplantation, the DR. DREAM Trial
Fred Hutchinson Cancer Center
Phase 1 Suspended
NCT04850495 2026-02-06
Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Suspended
NCT04309552 2026-01-27
Tumor Hypoxia and Proliferation in Patients With High-Grade Glioma
Weill Medical College of Cornell University
Phase 1 Suspended
NCT07353229 2026-01-23
68Ga-Dotatate PET and MRI Guided Radiation Dose Escalation for High Risk Meningioma
Thomas Jefferson University
Phase 1 Suspended
NCT06355908 2026-01-20
ENHANCING
Beijing Tiantan Hospital
Phase 1 Suspended
NCT06649682 2025-12-31
NYCRRLT
Peking Union Medical College Hospital
Phase 1 Suspended
NCT04840472 2025-12-24
Study Evaluating 111In-Panitumumab for Nodal Staging in Head and Neck Cancer
Stanford University
Phase 1 Suspended
NCT06709131 2025-11-24
CT0991
Zhejiang University
Phase 1 Suspended
NCT06388902 2025-11-21
A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies
BioRay Pharmaceutical Co., Ltd.
Phase 1 Suspended
NCT05938296 2025-11-19
oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection
Binhui Biopharmaceutical Co., Ltd.
Phase 1 Suspended
NCT06454409 2025-11-19
Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia
City of Hope Medical Center
Phase 1 Suspended
NCT06806228 2025-11-19
Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status)
Petrov, Andrey
Phase 1 Suspended
NCT07178665 2025-11-14
Pilot Trial of Preop Partial Radiation in Breast Cancer Patients
Rutgers, The State University of New Jersey
Phase 1 Suspended